Peptide reference
GHRP-2
Growth Hormone-Releasing Peptide 2 ·Pralmorelin ·KP-102 ·D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
What cited sources report about GHRP-2
GHRP-2 (pralmorelin, KP-102) is a synthetic hexapeptide ghrelin-receptor agonist of sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It is approved in Japan as pralmorelin (KP-102) for use in the diagnosis of growth hormone deficiency, but has no FDA-approved indication and no marketing authorization in the United States or European Union. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Li et al. (2024) — Arthroscopy
A preclinical study from the Sports Medicine Center and Department of Orthopedic Surgery at West China Hospital (Sichuan University) used a rat rotator-cuff-tear model to study GHRP-2 effects on tendon-bone healing. The authors observed in vitro suppression of M1 macrophage polarization markers (Cd86, Nos2, tnfa) and reported in vivo improvements in histologic scores, bone mineral density, biomechanical maximal failure load, and gait parameters in GHRP-2-treated animals at 4 and 8 weeks postsurgery.
GHRP-2 may be associated with decreased M1 macrophage production and increased histologic and biomechanical tendon-bone healing properties in a rat RCT model.
Mendias and Awan (2026) — Sports Medicine
A 2026 narrative review from the Performance Medicine Institute placed GHRP-2 alongside ipamorelin and other ghrelin-receptor-agonist peptides in the unapproved-peptide market discussion. The authors noted that animal-model evidence outpaces controlled human-trial evidence for these compounds, and that gray-market promotion direct-to-patient operates outside regulatory oversight.
Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.
PubChem CID 9919251 — National Center for Biotechnology Information
The PubChem record for pralmorelin catalogues the hexapeptide of sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, molecular formula C45H55N9O6, molecular weight 817.97 g/mol. Aggregated synonyms include KP-102 and pralmorelin hydrochloride; the record links to the supporting chemical and pharmaceutical literature.
DrugBank DB04898
The DrugBank entry classifies pralmorelin (GHRP-2) as approved in Japan as a diagnostic for growth hormone deficiency under the trade name Kaken Pralmorelin GHRP. The record reports that the compound has no U.S. marketing authorization and characterizes the ghrelin-receptor agonist mechanism.